KR102085052B1 - Composition for anti-inflammatory or moisturizing on skin comprising plant extract - Google Patents
Composition for anti-inflammatory or moisturizing on skin comprising plant extract Download PDFInfo
- Publication number
- KR102085052B1 KR102085052B1 KR1020160061627A KR20160061627A KR102085052B1 KR 102085052 B1 KR102085052 B1 KR 102085052B1 KR 1020160061627 A KR1020160061627 A KR 1020160061627A KR 20160061627 A KR20160061627 A KR 20160061627A KR 102085052 B1 KR102085052 B1 KR 102085052B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- skin
- composition
- inflammatory
- wipes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 32
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 27
- 239000000419 plant extract Substances 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 83
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 29
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 29
- 229940001448 feverfew extract Drugs 0.000 claims abstract description 26
- 235000020702 feverfew extract Nutrition 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 14
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 11
- 210000004209 hair Anatomy 0.000 claims description 10
- 244000192528 Chrysanthemum parthenium Species 0.000 claims description 9
- 235000008384 feverfew Nutrition 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 7
- 239000000516 sunscreening agent Substances 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000002781 deodorant agent Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 230000001815 facial effect Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000000475 sunscreen effect Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 241001180927 Trigonotis peduncularis Species 0.000 claims description 2
- 230000001166 anti-perspirative effect Effects 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000003213 antiperspirant Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 53
- 230000000694 effects Effects 0.000 abstract description 28
- 241000196324 Embryophyta Species 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 18
- 238000000605 extraction Methods 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 15
- 108010057466 NF-kappa B Proteins 0.000 description 14
- 102000003945 NF-kappa B Human genes 0.000 description 14
- 241000207923 Lamiaceae Species 0.000 description 13
- 239000008213 purified water Substances 0.000 description 13
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 12
- 108010063290 Aquaporins Proteins 0.000 description 11
- 230000028709 inflammatory response Effects 0.000 description 11
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- 102000010637 Aquaporins Human genes 0.000 description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- -1 and the like Natural products 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000341 volatile oil Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 5
- 229940113124 polysorbate 60 Drugs 0.000 description 5
- 235000013599 spices Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical group CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- 229940015975 1,2-hexanediol Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000179560 Prunella vulgaris Species 0.000 description 3
- 235000010674 Prunella vulgaris Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 240000007436 Cananga odorata Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 244000173853 Sanguisorba officinalis Species 0.000 description 2
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 2
- 244000305550 Streptopus amplexifolius Species 0.000 description 2
- 235000001231 Streptopus amplexifolius Nutrition 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940083980 lavender extract Drugs 0.000 description 2
- 235000020723 lavender extract Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009993 protective function Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PDNLXUROKBBMBE-BYOHNYAZSA-N (Z)-octadec-9-enoic acid (3R,4S,5R,6R)-3,4,5,6,7-pentahydroxyheptan-2-one Chemical compound CC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O PDNLXUROKBBMBE-BYOHNYAZSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000404046 Athanasia Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000007571 Cananga odorata Nutrition 0.000 description 1
- 102100021391 Cationic amino acid transporter 3 Human genes 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 241001632576 Hyacinthus Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 108091006230 SLC7A3 Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000404542 Tanacetum Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- YRIUSKIDOIARQF-UHFFFAOYSA-N dodecyl benzenesulfonate Chemical compound CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 YRIUSKIDOIARQF-UHFFFAOYSA-N 0.000 description 1
- 229940071161 dodecylbenzenesulfonate Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempherol Natural products C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940044591 methyl glucose dioleate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940079988 potassium cocoyl glycinate Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 일측면에 있어서 피버퓨 추출물, 꿀풀 추출물, 및 오이풀 추출물 중 하나 이상을 유효성분으로 포함하는 피부 항염 또는 피부 보습용 조성물에 관한 것으로서, 이러한 조성물은 천연 식물로부터 유래한 유효성분을 사용하여 부작용의 위험이 적고 안전성이 보장된 상태에서 우수한 피부 항염 효과를 나타내고 피부 보습 인자의 발현을 현저하게 촉진하여 우수한 피부 보습 효과를 나타낸다. 본 발명의 조성물은 화장품, 피부 외용제, 또는 위생용품에 사용될 수 있다. The present invention relates to a skin anti-inflammatory or skin moisturizing composition comprising, in one aspect, a feverfew extract, a nectar extract, and a cucumber extract as an active ingredient, the composition using an active ingredient derived from a natural plant. It shows an excellent skin anti-inflammatory effect in a state where the risk of side effects is low and safety is ensured, and the expression of skin moisturizing factor is markedly promoted, thereby showing an excellent skin moisturizing effect. The composition of the present invention can be used in cosmetics, external skin preparations, or hygiene products.
Description
본 발명은 식물 추출물, 구체적으로 피버퓨, 꿀풀, 및/또는 오이풀 추출물을 포함하는 피부 항염 또는 피부 보습용 조성물에 관한 것이다.The present invention relates to a skin anti-inflammatory or skin moisturizing composition comprising a plant extract, specifically feverfew, lamiaceae, and / or cucumber extract.
피부는 외부의 자극으로부터 몸을 보호하는 기능과 피부 내부로부터 수분 증발을 억제하여 인체의 항상성을 유지하는 역할을 하고 있다. 이러한 피부는 외부에 노출되어 있기 때문에 외부 요인이나 자극에 의하여 염증이 발생할 수 있으며, 피부를 건강하게 유지하기 위해서는 피부의 보습이 일정하게 유지되어야 한다. 피부에는 두피 및 모발이 포함될 수 있고, 이러한 기관도 외부 자극에 의해 염증이 발생할 수 있고 보습이 일정하게 유지되어야 할 필요성이 있다.The skin functions to protect the body from external stimuli and maintains homeostasis of the human body by inhibiting evaporation of moisture from inside the skin. Since the skin is exposed to the outside, inflammation may be caused by external factors or stimuli, and in order to keep the skin healthy, the moisture of the skin should be kept constant. The skin may include the scalp and hair, and these organs may also be inflamed by external stimuli and there is a need for constant moisturization.
염증은 조직이나 세포에 손상을 일으키는 원인이나 자극에 대해 그 반응을 최소화하고 원래대로 회복시키려는 목적으로 나타나는 현상이다. 피부에 염증을 일으키는 요인으로는 외상, 자외선, 화상, 고온, 방사능 등의 물리적인 원인과 화학적 요인 및 항체 반응에 의한 면역학적 요인, 환경 오염 물질 등에 의한 복합적인 요인 및 혈관이나 호르몬 불균형 등이 있다. Inflammation is a phenomenon aimed at minimizing and restoring a response to a cause or stimulus that causes damage to tissue or cells. Factors that cause skin irritation include physical causes such as trauma, ultraviolet rays, burns, high temperature, and radiation, chemical factors, immunological factors caused by antibody responses, complex factors caused by environmental contaminants, and blood vessel or hormonal imbalances. .
염증 원인의 제거 또는 생체 반응 및 증상을 감소시키는 항염 작용을 통해 이러한 염증을 최소화하거나 방지할 수 있다. 피부 염증을 치료하기 위하여 사용되는 물질 중 비스테로이드계로는 프루페나믹산, 이부프루펜, 벤지다민, 인도메타신 등이 있는데, 필수지방산의 일종인 아라키돈산이 사이클로옥시게나제 및 리폭시게나제와 반응하여 염증을 일으키는 세포독(leukotriene, prostaglandin)을 생성시키는 경우 사이클로옥시게나제와 반응하여 생합성되는 염증 유발물질은 차단할 수 있지만, 리폭시게나제와 반응하여 발생되는 염증 유발물질은 차단하지 못하여 피부 염증 치료 효과가 떨어지는 문제가 있다. 또한, 스테로이드계 염증 치료제로는 프레드니솔론, 덱사메타손 등이 효과가 있으나, 인체에 각종 부작용을 일으킬 수 있다. 스테로이드제를 장기간 피부에 도포하면 도포 부위의 피부에 털이 많아지고 피부가 위축될 수 있으며, 피부색소가 적어지고 세균의 감염이 생기며, 여드름이 돋고, 피부가 얇아지고 실핏줄이 드러나는 등의 부작용이 발생하는 경우가 있다. 심한 경우에는 호르몬에 의한 전신증상이 나타날 수 있으며, 처방(도포)을 중지하면 오히려 증상이 더 심해지므로 상기 스테로이드제의 사용을 중지할 수도 없게 된다. 또한, 아스피린, 인도메타신과 같은 종래의 염증 억제 성분들은 그 효과가 널리 인정되고 있으나 위장 장애, 항진성 혈관 확장 등의 부작용이 알려져 있고, 현재까지 알려진 항염 성분은 인체에 대한 안전성 측면, 제품 내 함유 시 안정성의 문제, 사용 함량 제한 등 법규 상의 문제들로 인해 그 사용 범위 및 수준이 제한적이다.Elimination of the cause of inflammation or anti-inflammatory action to reduce the biological response and symptoms can minimize or prevent this inflammation. Among the substances used to treat skin inflammation, nonsteroidal compounds include frupnamic acid, ibuprofen, benzidamine, and indomethacin, and arachidonic acid, an essential fatty acid, reacts with cyclooxygenase and lipoxygenase. To produce inflammatory cytotoxins (leukotriene, prostaglandin), which can block the biosynthetic inflammation that reacts with cyclooxygenase, but does not block the inflammation that occurs when it reacts with lipoxygenase. There is a problem that the effect is poor. In addition, as a steroid-based anti-inflammatory agent, prednisolone, dexamethasone, etc. are effective, but may cause various side effects in the human body. If steroid is applied to the skin for a long time, the skin at the site of application may have more hairs, shrink the skin, less skin pigment, bacterial infections, acne, thin skin, and blood vessels. There is a case. In severe cases, hormonal systemic symptoms may occur, and if the prescription (coating) is stopped, the symptoms become more severe, and thus the use of the steroid may not be stopped. In addition, conventional anti-inflammatory ingredients such as aspirin and indomethacin have been widely recognized for their effects, but side effects such as gastrointestinal disorders and antivascular vasodilation have been known. The scope and level of its use is limited due to legal issues such as stability issues and restrictions on use.
한편, 보습 기능은 피부를 건강하게 유지하는데 기본적인 속성으로, 보습이 적절히 유지되어야 피부 자체의 면역 기능과 보호 기능을 제대로 발휘할 수 있다. 가장 보편적으로 사용되는 보습 성분으로는 다가 알코올 혹은 다당류가 사용되고 있으나, 수산화기가 친수성을 띠어 피부에 도포 시에 외부로부터의 수분을 흡습하여 표피의 수분을 유지하는 기작으로 작용하므로 지속적인 보습 효과를 유지하지 못하는 단점이 있으며, 또한 사용감을 끈적이게 하고 다량을 제품에 함유할 경우 안정도에도 영향을 주며, 고가의 다당류의 경우 가격 경쟁력을 떨어뜨린다.On the other hand, the moisturizing function is a basic property to keep the skin healthy, moisturizing should be properly maintained to properly exhibit the immune function and protective function of the skin itself. The most commonly used moisturizing ingredients are polyhydric alcohols or polysaccharides.However, since the hydroxyl group is hydrophilic, it acts as a mechanism to keep moisture from the outside by absorbing moisture from the outside when applied to the skin. There is a disadvantage, it also makes the use of sticky feeling, and if the product contains a large amount, it also affects the stability, and expensive polysaccharides reduce the price competitiveness.
본 발명의 목적은 별도의 부작용을 발생시키지 않으면서, 염증 매개 인자의 억제를 통한 피부 항염 작용과 피부 내 수분 공급 인자의 발현 촉진을 통한 피부 보습 효과를 나타내어 피부를 보호하고 건강하게 유지시켜 주는 피부 항염 또는 피부 보습용 조성물을 제공하는 것에 있다.The purpose of the present invention is to protect the skin and keep it healthy by exhibiting a skin moisturizing effect through promoting the expression of the skin anti-inflammatory action through the inhibition of inflammatory mediators and promoting the expression of water supply factors without causing any side effects. It is providing the composition for anti-inflammatory or skin moisturizing.
상기 목적을 달성하기 위하여, 본 발명은 일 측면에 있어서 피버퓨 추출물, 꿀풀 추출물, 및 오이풀 추출물 중 하나 이상을 유효성분으로 포함하는 피부 항염 또는 피부 보습용 조성물을 제공한다.In order to achieve the above object, the present invention provides a skin anti-inflammatory or skin moisturizing composition comprising at least one of feverfew extract, nectar extract, and cucumber extract as an active ingredient.
또한, 본 발명의 일측면에 있어서, 이러한 피부 항염 또는 피부 보습용 조성물은 화장품, 피부 외용제, 또는 위생용품에 사용될 수 있다.In addition, in one aspect of the present invention, the skin anti-inflammatory or skin moisturizing composition may be used in cosmetics, external preparations for skin, or hygiene products.
본 발명의 일측면에 따른 피부 항염 조성물은 천연 식물로부터 유래한 유효성분을 사용하여 종래 염증 치료제에 비하여 부작용의 위험이 적고 안전성이 보장된 상태에서 현저하게 우수한 피부 항염 효과를 나타낸다. Skin anti-inflammatory composition according to an aspect of the present invention, using an active ingredient derived from a natural plant exhibits a remarkably excellent skin anti-inflammatory effect in a state where the risk of side effects and safety is guaranteed as compared to conventional inflammatory therapeutics.
또한, 본 발명의 일측면에 따른 피부 보습용 조성물은 피부 보습과 관련된 인자의 발현을 현저하게 촉진하여 우수하고 지속적인 보습 효과를 제공하고 제품 사용시 안정도가 보장되고 가격 경쟁력이 우수한 제품을 제조할 수 있는 효과를 나타낸다.In addition, the composition for moisturizing the skin according to an aspect of the present invention significantly promotes the expression of factors related to skin moisturizing, provides an excellent and lasting moisturizing effect, and ensures stability when using the product and produces a product having excellent price competitiveness. Indicates.
도 1는 자외선B(UVB, Ultraviolet B)에 의해 유도된 염증 반응에서 본 발명의 일측면에 따른 실시예의 TNF-α(조직 괴사 인자)에 대한 발현 저해 정도를 나타낸 그래프이다.
도 2는 UVB에 의해 유도된 염증 반응에서 본 발명의 일측면에 따른 실시예의 NF-κB(세포 핵 전사인자)에 대한 발현 저해 정도를 나타낸 그래프이다.
도 3은 과산화수소수에 의해 유도된 염증 반응에서 본 발명의 일측면에 따른 실시예의 TNF-α에 대한 발현 저해 정도를 나타낸 그래프이다.
도 4은 과산화수소수에 의해 유도된 염증 반응에서 본 발명의 일측면에 따른 실시예의 NF-κB에 대한 발현 저해 정도를 나타낸 그래프이다.
도 5는 본 발명의 일측면에 따른 실시예의 피부 보습 인자인 히알루론합성효소-3(hyaluronan synthase-3, HAS-3)에 대한 발현 촉진 정도를 나타낸 그래프이다.
도 6은 본 발명의 일측면에 따른 실시예의 피부 보습 인자인 아쿠아포린에 대한 발현 촉진 정도를 나타낸 그래프이다.Figure 1 is a graph showing the degree of inhibition of expression for TNF-α (tissue necrosis factor) of the embodiment according to an aspect of the present invention in the inflammatory response induced by UVB (UVB, Ultraviolet B).
Figure 2 is a graph showing the degree of inhibition of expression for NF-κB (cell nuclear transcription factor) of the embodiment according to an aspect of the present invention in the inflammatory response induced by UVB.
Figure 3 is a graph showing the degree of inhibition of expression for TNF-α of the embodiment according to an aspect of the present invention in the inflammatory response induced by hydrogen peroxide.
Figure 4 is a graph showing the degree of inhibition of expression for NF-κB of the embodiment according to an aspect of the present invention in the inflammatory response induced by hydrogen peroxide solution.
Figure 5 is a graph showing the expression promoting degree for hyaluronan synthase-3 (HAS-3), which is a skin moisturizing factor of an embodiment of the present invention.
Figure 6 is a graph showing the expression promoting degree for the skin moisturizing factor aquaporin of the embodiment according to an aspect of the present invention.
본 발명의 일측면에 있어서, “피부”는 생물의 외부를 덮고 있는 기관으로서 기관의 바깥쪽에서부터 표피, 진피 및 피하지방층으로 구성되고 얼굴 또는 몸 전체의 외부를 덮는 조직뿐만 아니라, 두피 및 모발을 포함하는 가장 넓은 개념이다.In one aspect of the invention, the "skin" is an organ covering the exterior of the organism, consisting of the epidermis, dermis and subcutaneous fat layer from the outside of the organ and covering the scalp and hair as well as tissue covering the outside of the face or the entire body. It is the broadest concept to include.
본 발명의 일측면에 있어서, “추출물”은 추출을 수행하는 방법, 추출 용매, 추출된 성분 또는 추출물의 형태와 무관하게, 천연물로부터 수득된 물질을 모두 포함하는 것이며 또한 천연물로부터 수득된 물질을 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질까지도 모두 포함하는 광범위한 개념이다.In one aspect of the invention, an “extract” includes all materials obtained from natural products and extracts materials obtained from natural products, regardless of the method of carrying out the extraction, the extraction solvent, the extracted components or the form of the extract. It is a broad concept that includes all materials that can be obtained after processing or processing in other ways.
본 발명의 일 측면에 있어서, “피버퓨 추출물,” “꿀풀 추출물,” “오이풀 추출물”은 각 식물을 원료로 추출을 수행하여 수득된 물질을 모두 포함하는 것이며, 예를 들어 추출을 수행하는 과정에서 열, 산, 염기, 효소 등으로 식물을 처리할 수 있고, 이렇게 식물로부터 수득된 물질을 추출 후 다른 방법으로 가공 처리하여 수득되는 물질까지도 모두 포함하는 광범위한 개념이다.In one aspect of the invention, "fiberfew extract," "honey extract," "cucumber extract" is to include all the materials obtained by performing the extraction of each plant as a raw material, for example the process of performing the extraction It is possible to treat plants with heat, acids, bases, enzymes, and the like, and this is a broad concept that includes all materials obtained by extracting and then processing the materials obtained from plants.
본 발명의 일측면에 있어서, “피버퓨(Tanacetum parthenium),” “꿀풀(Prunella vulgaris),” 및 “오이풀(Sanguisorba officinalis)”은 각 식물 초본의 어린순, 잎, 꽃, 줄기, 껍질, 열매, 종자, 뿌리 및 이들의 조합으로 구성된 군으로부터 선택된 하나 이상일 수 있다.In one aspect of the present invention, “ Tanacetum parthenium ,” “ Prunella vulgaris ,” and “ Sanguisorba officinalis ” are the young plants, leaves, flowers, stems, bark, fruit, At least one selected from the group consisting of seed, root and combinations thereof.
이하에서는 본 발명에 대하여 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 일측면에 있어서, 피버퓨 추출물, 꿀풀 추출물, 및 오이풀 추출물 중 하나 이상을 유효성분으로 포함하는 피부 항염 조성물에 관한 것일 수 있다.In one aspect, the present invention may be directed to a skin anti-inflammatory composition comprising one or more of feverfew extract, nectar extract, and cucumber extract as an active ingredient.
본 발명은 일측면에 있어서, 피버퓨 추출물, 꿀풀 추출물, 및 오이풀 추출물 중 하나 이상을 유효성분으로 포함하는 피부 보습용 조성물에 관한 것일 수 있다.In one aspect, the present invention may be directed to a skin moisturizing composition comprising at least one of feverfew extract, nectar extract, and cucumber extract as an active ingredient.
피버퓨(Tanacetum parthenium)는 남, 동 유럽에서 아시아까지 분포하는 여러해살이풀로, 여름백국 또는 화란국화라고도 부른다. 속명인 타나세툼(Tanacetum)은 그리스어 ‘athanasia’에서 비롯되었으며, 열을 내리는 효과가 있어 ‘feverfew’라는 이름이 붙었다. 현재까지 밝혀진 피버퓨의 구성 성분으로는 베타-카로텐(beta-carotene), 파르테노리드(parthenolide), 칼슘, 철, 마그네슘, 망간, 인, 칼륨, 셀렌, 아연, 비타민 B1, B2, B3, C, 세스키테르핀 락톤(sesquiterpene lactone), 휘발성 오일, 타닌, 모노테르핀 등이다.Feverfew ( Tanacetum parthenium ) is a perennial herb that is distributed from South and Eastern Europe to Asia and is also called summer white or feverfew. The generic name Tanacetum comes from the Greek 'athanasia' and is called 'feverfew' because of its heat-reducing effect. The components of feverfew discovered to date include beta-carotene, parthenolide, calcium, iron, magnesium, manganese, phosphorus, potassium, selenium, zinc, vitamins B1, B2, B3, C , Sesquiterpene lactone, volatile oils, tannins, monoterpins and the like.
본 발명의 일측면에 있어서, 피버퓨 추출물은 피버퓨 초본의 잎, 꽃, 줄기, 뿌리 및 이들의 조합으로 구성된 군으로부터 선택된 하나 이상의 추출물일 수 있다.In one aspect of the invention, the feverfew extract may be one or more extracts selected from the group consisting of feverfew herb leaves, flowers, stems, roots, and combinations thereof.
꿀풀(Prunella vulgaris)은 하고초, 꿀방망이로도 불리는 여러해살이풀이며 우리 나라와 중국, 일본 등지에 널리 분포한다. 밀원식물로, 과거에는 꽃을 따서 꿀을 빨아 먹기도 했다. 꿀풀의 초본 전체에는 우르솔릭산(ursolic acid), 카페인산, 로즈마리산, 카로티노이드, 타닌, 유기산 등이 함유되어 있으며, 꽃의 구성성분으로 사포닌, 트리테르펜, 플라보노이드류, 스테롤 및 지방산 등이 있다. Prunella vulgaris ( Prunella vulgaris ) is a perennial herb, also called hyacinth and honey bat, widely distributed in Korea, China, and Japan. As a wheat plant, it used to pick flowers and suck honey. The entire herbaceous herb contains ursolic acid, caffeic acid, rosemary acid, carotenoids, tannins, organic acids, and the like, and saponins, triterpenes, flavonoids, sterols, and fatty acids are constituents of flowers.
본 발명의 일측면에 있어서, 꿀풀 추출물은 꿀풀 초본의 어린순, 잎, 꽃, 줄기 및 이들의 조합으로 구성된 군으로부터 선택된 하나 이상의 추출물일 수 있다.In one aspect of the invention, the nectar extract may be one or more extracts selected from the group consisting of young shoots, leaves, flowers, stems, and combinations thereof of nectar herb.
오이풀(Sanguisorba officinalis)은 장미과에 속하는 여러해살이풀로, 한방에서는 오이풀뿌리를 지유라고 부른다. 오이풀 뿌리의 성분으로는 약 17%의 탄닌과 사포닌이 함유되어 있고, 그 외에 갈산, 우르솔릭산, 엘라그산(ellagic acid), 쿼세틴(quercetin) 배당체, 캠페롤(kaempferol) 배당체, 류코안토시아니딘(leucoanthocyanidin) 등이 알려져 있다.Cucumber ( Sanguisorba officinalis ) is a perennial herb belonging to the family Rosaceae, and in oriental medicine, cucumber roots are called fat milk. Cucumber roots contain about 17% of tannins and saponins, as well as gallic acid, ursolic acid, ellagic acid, quercetin glycosides, kaempferol glycosides, and leucoanthocyanidins. (leucoanthocyanidin) and the like are known.
본 발명의 일측면에 있어서, 오이풀 추출물은 오이풀 초본의 뿌리 추출물일 수 있다.In one aspect of the invention, cucumber extract may be root extract of cucumber herbal.
본 발명의 일측면에 있어서, 조성물 총 부피에 대하여 추출물의 총 함량은 0.0001 내지 20 부피%, 0.001 내지 15 부피%, 0.05 내지 10 부피%, 0.1 내지 5 부피%, 0.5 내지 2 부피%, 0.8 내지 1.2 부피% 일 수 있다. 또한, 조성물 총 부피에 대하여 추출물의 총 함량은 예를 들어 1.0 부피% 일 수 있다. 추출물의 총 함량이 지나치게 소량이면 본 발명의 목적을 달성하기 위한 피부 항염 또는 피부 보습 효과를 나타낼 수 없고, 지나치게 과량이면 사용되는 제형에 영향을 미칠 수 있다. In one aspect of the invention, the total content of the extract relative to the total volume of the composition is 0.0001 to 20% by volume, 0.001 to 15% by volume, 0.05 to 10% by volume, 0.1 to 5% by volume, 0.5 to 2% by volume, 0.8 to It may be 1.2% by volume. In addition, the total content of the extract relative to the total volume of the composition may be, for example, 1.0% by volume. If the total content of the extract is too small, it may not exhibit the skin anti-inflammatory or skin moisturizing effect to achieve the object of the present invention, and if excessively excessive, it may affect the formulation used.
본 발명의 일측면에 있어서, 추출물은 물; 유기용매; 및 이들의 혼합물로 이루어진 군에서 선택된 하나 이상으로 추출한 것일 수 있다.In one aspect of the invention, the extract is water; Organic solvents; And it may be extracted with one or more selected from the group consisting of a mixture thereof.
본 발명의 일측면에 있어서, 물은 증류수 또는 정제수를 포함하며, 유기 용매는 C1~C6의 저급 알코올, 아세톤, 에테르, 프로판디올, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤, 클로로포름, 헥산, 메틸렌 클로라이드, 에틸 아세테이트, 부틸렌글리콜, 헥산디올 및 프로필렌글리콜로 이루어진 군에서 선택된 하나 이상을 포함하나, 이에 제한되는 것은 아니다.In one aspect of the invention, the water comprises distilled or purified water, the organic solvent is C1 ~ C6 lower alcohol, acetone, ether, propanediol, ethyl acetate, diethyl ether, ethyl methyl ketone, chloroform, hexane, methylene One or more selected from the group consisting of chloride, ethyl acetate, butylene glycol, hexanediol and propylene glycol, but is not limited thereto.
본 발명의 일측면에 있어서, 상기 추출물은 정제수, 1,3-부틸렌글리콜 및 1,2-헥산디올의 혼합용매로 추출된 것일 수 있다. 예를 들어, 상기 혼합용매는 그 총 질량을 기준으로 60 내지 75 질량%의 정제수, 24 내지 35 질량%의 1,3-부틸렌글리콜 및 1 내지 5 질량%의 1,2-헥산디올을 포함하는 것일 수 있다. 또한, 상기 혼합용매에 포함된 정제수의 함량은 혼합용매의 총 질량에 대하여 60 내지 75 질량%, 63 내지 73 질량%, 또는 65 내지 70 질량%일 수 있으며; 1,3-부틸렌글리콜의 함량은 혼합용매의 총 질량에 대하여 20 내지 40 질량%, 25 내지 35 질량%, 또는 28 내지 32 질량%일 수 있으며; 1,2-헥산디올의 함량은 혼합용매의 총 질량에 대해 0.1 내지 7 질량%, 1 내지 5 질량%, 또는 2 내지 4 질량%일 수 있으나, 이에 제한되지는 않는다.In one aspect of the invention, the extract may be extracted with a mixed solvent of purified water, 1,3-butylene glycol and 1,2-hexanediol. For example, the mixed solvent includes 60 to 75 mass% of purified water, 24 to 35 mass% of 1,3-butylene glycol and 1 to 5 mass% of 1,2-hexanediol based on the total mass of the mixed solvent. It may be. In addition, the content of the purified water contained in the mixed solvent may be 60 to 75 mass%, 63 to 73 mass%, or 65 to 70 mass% with respect to the total mass of the mixed solvent; The content of 1,3-butylene glycol may be 20 to 40 mass%, 25 to 35 mass%, or 28 to 32 mass% with respect to the total mass of the mixed solvent; The content of 1,2-hexanediol may be 0.1 to 7% by mass, 1 to 5% by mass, or 2 to 4% by mass relative to the total mass of the mixed solvent, but is not limited thereto.
본 발명의 일 측면에 있어서, 상기 추출물은 예를 들어, 열수 추출, 가열 추출, 냉침 추출, 환류 추출, 환류 냉각 추출, 또는 초음파 추출 등을 이용하여 추출될 수 있고 통상의 기술자에게 자명한 추출 공정이라면 제한되지 않는다. 추출물의 추출은 실온에서 수행될 수 있으나 효율적인 추출을 위해 약 40 내지 120℃, 80 내지 110℃, 또는 90 내지 100℃의 조건에서 추출 할 수 있으며, 구체적으로 약 95℃의 온도와 같은 가온 조건에서 추출할 수 있으나, 이에 제한되는 것은 아니다. 추출시간은 약 1 내지 4시간, 구체적으로는 약 1.5 내지 2.5 시간 동안 수행할 수 있으나 이에 제한되는 것은 아니며, 이는 추출 용매 및 추출 온도 등의 조건에 따라 달라질 수 있다. 예를 들어, 추출 용매가 물인 경우에는 90 내지 100℃, 에탄올인 경우에는 65 내지 70℃에서 수행될 수 있다. 추출은 유효성분의 추출 수득량을 높이기 위해 1회 이상 여러 번 추출할 수 있으며, 예를 들어 1 내지 5회로 연속 추출하여 합한 추출액을 이용할 수 있다.In one aspect of the present invention, the extract can be extracted using, for example, hot water extraction, heat extraction, cold extraction, reflux extraction, reflux cooling extraction, or ultrasonic extraction and the like, which will be apparent to those skilled in the art. Is not limited. Extraction of the extract may be carried out at room temperature, but for efficient extraction may be extracted at the conditions of about 40 to 120 ℃, 80 to 110 ℃, or 90 to 100 ℃, specifically at a heating condition such as a temperature of about 95 ℃ Can be extracted, but is not limited thereto. Extraction time may be performed for about 1 to 4 hours, specifically about 1.5 to 2.5 hours, but is not limited thereto. The extraction time may vary depending on conditions such as extraction solvent and extraction temperature. For example, when the extraction solvent is water, it may be carried out at 90 to 100 ℃, 65 to 70 ℃ if ethanol. The extraction may be extracted one or more times in order to increase the extraction yield of the active ingredient, for example, may be used by extracting the combined successive extraction 1 to 5 times.
피부에서의 염증 반응으로는 혈관 확장, 혈류 변화, 백혈구의 조직 내 침윤과 같은 생리적 현상이 나타나며 이로 인해 발적(redness), 발열, 팽윤, 및 통증 등의 증상뿐만 아니라, 혈관 투과성의 증가와 함께 항체 및 대식 세포 등이 염증 부위로 집중되면서 홍반의 원인이 되기도 한다. 이러한 염증 반응에는 다양한 생화학적 현상이 관여하는데, TNF-α와 같은 염증성 사이토카인에 의해 유도되는 산화질소 합성효소(nitric oxide synthase, NOS)가 염증 반응의 중요한 매개체로 알려져 있다.Inflammatory reactions in the skin include physiological phenomena such as vasodilation, changes in blood flow, and infiltration of leukocytes in tissues, resulting in an increase in vascular permeability, as well as symptoms of redness, fever, swelling, and pain. And macrophages, etc. are concentrated to the site of inflammation may cause erythema. Various biochemical phenomena are involved in this inflammatory response. Nitric oxide synthase (NOS) induced by inflammatory cytokines such as TNF-α is known as an important mediator of the inflammatory response.
본 발명의 일측면에 따른 조성물은 염증 반응에 관여하는 사이토카인인 TNF-α의 분비를 억제하고 NF-κB의 발현을 저해하여 피부 항염 활성 효과를 나타낸다.The composition according to one aspect of the present invention inhibits the secretion of TNF-α, a cytokine involved in the inflammatory response, and inhibits the expression of NF-κB, thereby exhibiting an anti-inflammatory activity.
한편, 건강한 인체 피부의 수분은 피부의 탄력성 및 유연성을 지탱해 주며, 적절한 수분 함량이 유지되어야 피부 자체의 보호 기능과 면역 기능을 발휘할 수 있다. 각질층의 수분이 10% 이하일 경우, 피부는 건성화되고 피부 트러블의 원인이 된다고 알려져 있다. 아쿠아포린(aquaporin)은 세포막에서 물 분자의 출입을 조절하는 막 단백질로, 피부 내의 수분보유량을 증가시키는 역할을 한다. 또한, 콜라젠 및 엘라스틴과 같은 단백질과 함께 세포 외 기질의 주요 구성 성분인 히알루론산은 다당류인 글라이코스아미노글라이칸(GAG)의 일종으로, 피부가 충분한 수분을 함유할 수 있도록 하는 수분 흡착제로서의 기능을 수행한다. 히알루론산을 합성하는 효소인 HAS-3의 양을 증가시키면 히알루론산의 합성을 촉진하여 피부의 수분보유량 및 보습 유지력를 향상시키게 된다.On the other hand, the moisture of healthy human skin supports the elasticity and flexibility of the skin, and the proper moisture content can be maintained to exhibit the protective function and immune function of the skin itself. If the moisture in the stratum corneum is less than 10%, the skin is known to dry out and cause skin trouble. Aquaporin is a membrane protein that regulates the entry and exit of water molecules in cell membranes and increases water retention in the skin. In addition, along with proteins such as collagen and elastin, hyaluronic acid, a major component of the extracellular matrix, is a polysaccharide glycosaminoglycan (GAG) that functions as a moisture adsorbent that allows the skin to contain sufficient moisture. To perform. Increasing the amount of HAS-3, an enzyme that synthesizes hyaluronic acid, promotes the synthesis of hyaluronic acid, thereby improving skin moisture retention and moisturizing retention.
본 발명의 일측면에 따른 조성물은 아쿠아포린의 합성을 촉진하고 HAS-3을 증가시켜 피부의 수분 보유력을 향상시키고 피부의 보습 강화 작용을 나타내므로, 피부를 보호하고 건강하게 유지시키는 효과를 나타낸다.The composition according to one aspect of the present invention promotes the synthesis of aquaporin and increases the HAS-3, thereby improving the moisture retention of the skin and exhibiting a moisturizing action of the skin, thereby exhibiting the effect of protecting and maintaining the skin.
본 발명의 일측면에 있어서, 상기 조성물은 피버퓨 추출물, 꿀풀 추출물 및 오이풀 추출물 중의 2 이상의 조합을 유효성분으로 포함할 수 있다. 본 발명의 일측면에 따른 조성물은 피버퓨 추출물, 꿀풀 추출물 및 오이풀 추출물 중의 2 이상의 조합에 의하여 이들 각각을 포함하는 경우에 비해 현저하게 우수한 피부 항염 효과 및 피부 보습 효과를 나타낸다.In one aspect of the present invention, the composition may include a combination of two or more of feverfew extract, nectar extract and cucumber extract as an active ingredient. The composition according to one aspect of the present invention exhibits a remarkably superior skin anti-inflammatory effect and skin moisturizing effect compared to the case comprising each of them by a combination of two or more of feverfew extract, lamiaceae extract and cucumber extract.
본 발명의 일측면에 있어서, 상기 조성물에서 피버퓨 추출물:꿀풀 추출물:오이풀 추출물의 부피비는 1~9:1~9:1~9 의 정수 비일 수 있다. 구체적으로, 상기 조성물에서 피버퓨 추출물:꿀풀 추출물:오이풀 추출물의 부피비는 1~5:1~5:1~5, 1~3:1~3:1~3, 1~2.7:1~2.7:1~2.7, 1~2.3:1~2.3:1~2.3, 또는 1~2:1~2:1~2일 수 있다. 또한, 상기 조성물에서 피버퓨 추출물:꿀풀 추출물:오이풀 추출물의 부피비는 예를 들어 약 2:1:2일 수 있다.In one aspect of the present invention, the volume ratio of feverfew extract: Lamiaceae extract: Cucumber extract in the composition may be an integer ratio of 1 ~ 9: 1 ~ 9: 1 ~ 9. Specifically, the volume ratio of Feverfew extract: Lavender extract: Cucumber extract in the composition is 1-5: 1-5: 1-5, 1-3: 1-3: 1-3, 1-2.7: 1-2.7: It can be 1 to 2.7, 1 to 2.3: 1 to 2.3: 1 to 2.3, or 1 to 2: 1 to 2: 1 to 2. In addition, the volume ratio of the Feverfew extract: Lavender extract: Cucumber extract in the composition may be about 2: 1: 2, for example.
본 발명의 일측면에 있어서, 상기 조성물은 본 발명의 효과를 저해하지 않는 범위 내에서 통상의 기술자가 자명하게 적용할 수 있는 통상적이고 공지된 성분으로 항산화제, 보존제, 흡수제, 각질제거제, 증점제, 선크림제제, 유화제, 계면활성제, 향료, 소취제, 안정화제, 피부 보호제, 및 pH 조절제 중 하나 이상을 더 포함할 수 있다.In one aspect of the present invention, the composition is a conventional and known components that can be obviously applied to those skilled in the art within the range that does not impair the effects of the present invention, antioxidants, preservatives, absorbents, exfoliants, thickeners, It may further comprise one or more of a sunscreen, emulsifiers, surfactants, fragrances, deodorants, stabilizers, skin protectants, and pH adjusting agents.
본 발명의 일측면에 있어서, 항산화제는 본 발명의 효과를 저해하지 않는 범위 내에서 토코페릴아세테이트, 토코페롤, 디부틸히드록시톨루엔(BHT), 아세틸 시스테인, 아스코르브산 폴리펩타이드, 에리소르빈산, 디아밀하이드로퀴논 및 아스코르빌 팔미테이트로 구성된 군으로부터 선택된 하나 이상 일 수 있다. 항산화제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the antioxidant is tocopheryl acetate, tocopherol, dibutylhydroxytoluene (BHT), acetyl cysteine, ascorbic acid polypeptide, erythorbic acid, diamyl within the range that does not impair the effects of the present invention At least one selected from the group consisting of hydroquinone and ascorbyl palmitate. Antioxidants are conventionally used content may be included, for example, but not limited to 0.01 to 2% by weight relative to the total weight of the composition.
본 발명의 일측면에 있어서, 보존제는 본 발명의 효과를 저해하지 않는 범위 내에서 메틸파라벤, 프로필파라벤, 페녹시에탄올, 포타슘소르베이트, 데하이드로 아세트산(Dehydroacetic Acid), 펜탄디올 및 소르브산으로 구성된 군으로부터 선택된 하나 이상 일 수 있다. 보존제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the preservative is composed of methylparaben, propylparaben, phenoxyethanol, potassium sorbate, dehydroacetic acid, pentanediol and sorbic acid within the scope of not impairing the effects of the present invention. It may be one or more selected from the group. Preservatives are conventionally used content may be included, for example, but not limited to 0.01 to 2% by weight relative to the total weight of the composition.
본 발명의 일측면에 있어서, 흡수제는 알루미늄 전분 옥테닐숙신에이트, 카올린, 옥수수 전분, 오트 전분, 시클로덱스트린, 탈크, 및 제올라이트로 구성된 군으로부터 선택된 하나 이상일 수 있다. 흡수제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the absorbent may be one or more selected from the group consisting of aluminum starch octenylsuccinate, kaolin, corn starch, oat starch, cyclodextrin, talc, and zeolite. Absorbents are conventionally used, for example, but may be included, but is not limited to, 0.01 to 2% by weight relative to the total weight of the composition.
본 발명의 일측면에 있어서, 각질제거제는 알파-히드록시산, 베타-히드록시산, 락트산, 글리콜산, 살리실산 및 이의 염으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 각질제거제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the exfoliating agent may be one or more selected from the group consisting of alpha-hydroxy acid, beta-hydroxy acid, lactic acid, glycolic acid, salicylic acid and salts thereof. Exfoliants are conventionally used amounts, for example, may be included in 0.01 to 2% by weight relative to the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 증점제는 카르복실산 폴리머(예를 들어, 아크릴산), 파라핀, 가교된 폴리아크릴레이트 폴리머, 폴리아크릴아미드 폴리머(예를 들어, 폴리아크릴아미드, 또는 이소파라핀), 폴리사카라이드(예를 들어 셀룰로오스), 및 검(예를 들어, 한천, 알긴, 알긴산암모늄, 또는 젤라틴)으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 증점제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the thickeners are carboxylic acid polymers (eg acrylic acid), paraffins, crosslinked polyacrylate polymers, polyacrylamide polymers (eg polyacrylamides, or isoparaffins), poly At least one selected from the group consisting of saccharides (eg cellulose), and gums (eg, agar, algin, ammonium alginate, or gelatin). Thickeners are conventionally used amounts, for example, may be included in 0.01 to 2% by weight relative to the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 선크림제제는 파라-아미노벤조산(PABA), 글리세릴 PABA, 옥틸디메틸 PABA, 부틸 PABA, 신나메이트, 안트라닐레이트, 살리실레이트, 카올린, 탈크, 페트롤라툼, 및 메탈 옥사이드로 구성된 군으로부터 선택된 하나 이상일 수 있다. 선크림제제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the sunscreen preparation is para-aminobenzoic acid (PABA), glyceryl PABA, octyldimethyl PABA, butyl PABA, cinnamate, anthranilate, salicylate, kaolin, talc, petrolatum, and metals It may be at least one selected from the group consisting of oxides. Sunscreen preparations are conventionally used content may be included, for example, 0.01 to 2% by weight relative to the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 유화제는 본 발명의 효과를 저해하지 않는 범위 내에서 밀납, 세테아릴 글루코사이드, 카르복시비닐폴리머, 폴리솔베이트 20, 폴리솔베이트 60, 도데실벤젠술폰산염, 소르비탄 지방산 에스테르, 모노스테아르산 글리세린, 스테아르산, 팔미트산, 스테아릴 알코올, 베헤닐 알코올, 및 레시틴으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 이러한 유화제는 조성물의 총 중량에 대해 0.01 내지 4 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the emulsifier is beeswax, cetearyl glucoside, carboxyvinyl polymer,
본 발명의 일측면에 있어서, 계면활성제는 본 발명의 효과를 저해하지 않는 범위 내에서 소르비탄세스퀴올레이트, 디소듐코코암포디아세테이트, 소듐코코암포아세테이트, 피이지-12 노닐페닐에테르, 피이지-120메틸글루코오스디올리에이트, 및 포타슘코코일글리시네이트로 구성된 군으로부터 선택된 하나 이상일 수 있다. 계면활성제는 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the present invention, the surfactant is sorbitan sesquioleate, disodium coco ampoacetate, sodium coco ampoacetate, fiji-12 nonylphenyl ether, and sebum within a range that does not impair the effects of the present invention. At least one selected from the group consisting of -120 methylglucose dioleate, and potassium cocoylglycinate. The surfactant may be included in 0.01 to 2% by weight relative to the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 향료는 허브, 일랑일랑 정유, 오렌지 정유, 카난가 정유, 계피정유, 케모마일 꽃추출물, 레몬 글래스 정유, 레몬 정유, 및 로즈마리 정유로 구성된 군으로부터 선택된 하나 이상일 수 있다. 향료는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the fragrance may be one or more selected from the group consisting of herbs, ylang-ylang essential oil, orange essential oil, cananga essential oil, cinnamon essential oil, chamomile flower extract, lemon glass essential oil, lemon essential oil, and rosemary essential oil. Perfume may be included in the conventionally used content, for example, 0.01 to 2% by weight relative to the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 소취제는 과망간산 칼륨, 표백분, 편백나무추출물, 대나무 추출물, 녹차 추출물, 솔잎 추출물, 및 레몬즙으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 소취제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다. In one aspect of the invention, the deodorant may be one or more selected from the group consisting of potassium permanganate, bleach powder, cypress extract, bamboo extract, green tea extract, pine needle extract, and lemon juice. Deodorant is a conventionally used content and may include, for example, 0.01 to 2% by weight relative to the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 안정화제는 아황산나트륨, 아스코르빈산, 카로티노이드, 레티놀, 티오글리세롤, 및 시스테인으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 안정화제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다. In one aspect of the invention, the stabilizer may be one or more selected from the group consisting of sodium sulfite, ascorbic acid, carotenoids, retinol, thioglycerol, and cysteine. Stabilizers are conventionally used content may be included, for example, but not limited to 0.01 to 2% by weight relative to the total weight of the composition.
본 발명의 일측면에 있어서, 피부 보호제는 카프릴릭/카프릭 트리글리세라이드, 세테아릴 알코올, 스쿠알란, 알란토인, 베타글루칸, 히알루론산 추출물, 로즈마리 추출물, 토코페릴 아세테이트, 콜로스트럼, 알란토인, 및 D-판테놀로 구성된 군으로부터 선택된 하나 이상일 수 있다. 피부 보호제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다. In one aspect of the invention, the skin protectant is caprylic / capric triglyceride, cetearyl alcohol, squalane, allantoin, betaglucan, hyaluronic acid extract, rosemary extract, tocopheryl acetate, colostrum, allantoin, and At least one selected from the group consisting of D-panthenol. Skin protectants can be included, but are not limited to, amounts typically used, for example, from 0.01 to 2% by weight relative to the total weight of the composition.
본 발명의 일측면에 있어서, pH 조절제는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨. 트리에탄올아민 및 탄산 칼슘으로 구성된 군으로부터 선택된 하나 이상일 수 있다. pH 조절제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the invention, the pH adjusting agent is citric acid, sodium citrate, malic acid, sodium malate, fmaric acid, sodium pmarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate. At least one selected from the group consisting of triethanolamine and calcium carbonate. pH adjusters are conventionally used content, for example, may be included, but is not limited to 0.01 to 2% by weight relative to the total weight of the composition.
본 발명의 일측면에 있어서, 상기 조성물은 화장품, 피부 외용제, 또는 위생용품에 사용될 수 있다.In one aspect of the invention, the composition can be used in cosmetics, external preparations for skin, or hygiene products.
본 발명의 일측면에 있어서, 화장품은 화장수, 에센스, 선크림, 선로션, 크림류 등과 같은 기초 화장품; 가루분, 고형백분, 크림백분, 파운데이션, 입술연지, 눈썹연필, 미조료 등과 같은 메이크업 화장품; 헤어 로션, 헤어 토닉, 액상 및 유상 정발료, 헤어 크림, 헤어 트리트먼트 크림, 샴푸, 헤어 스프레이 등과 같은 헤어케어 화장품; 팩과 같은 얼굴 케어 화장품; 또는 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저 등과 같은 바디케어 화장품일 수 있다.In one aspect of the invention, the cosmetic is a cosmetic, such as a lotion, essence, sun cream, sun lotion, creams; Makeup cosmetics such as powdered powder, solid white powder, cream white powder, foundation, lip balm, eyebrow pencil, unflavored powder, etc .; Hair care cosmetics such as hair lotions, hair tonics, liquid and oil-based hair dressings, hair creams, hair treatment creams, shampoos, hair sprays, and the like; Facial care cosmetics such as packs; Or body care cosmetics such as soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
본 발명의 일측면에 있어서, 피부 외용제는 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 및 겔제로 구성된 군으로부터 선택된 어느 하나 일 수 있다. In one aspect of the invention, the external preparation for the skin may be any one selected from the group consisting of ointments, lotions, sprays, patches, creams, powders, suspensions, and gels.
본 발명의 일측면에 있어서, 위생용품은 물티슈, 티슈, 기저귀, 생리대, 위생 와이프, 습윤 와이프, 클리닝 와이프, 훼이셜 와이프, 스킨케어 와이프, 및 지한제 와이프로 구성된 군으로부터 선택된 어느 하나일 수 있다.In one aspect of the invention, the hygiene article may be any one selected from the group consisting of wet wipes, tissues, diapers, sanitary napkins, sanitary wipes, wet wipes, cleaning wipes, facial wipes, skin care wipes, and antiperspirant wipes.
이하, 실시예 및 시험예를 들어 본 명세서의 구성 및 효과를 보다 구체적으로 설명한다. 그러나 이들 실시예 및 시험예는 본 명세서에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 명세서의 범주 및 범위가 하기 예에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present specification will be described in more detail with reference to Examples and Test Examples. However, these examples and test examples are provided only for the purpose of illustration to help the understanding of the present specification, the scope and scope of the present specification is not limited by the following examples.
[실시예 1~4, 대조예 및 비교예][Examples 1-4, a control example, and a comparative example]
(1) 피버퓨 초본의 잎, 꽃, 줄기, 및 뿌리로 구성된 혼합물을 1:20의 중량비로 추출 용매(정제수 67 질량%, 1,3-부틸렌 글리콜 30 질량%, 및 1,2-헥산디올 3 질량%로 구성됨)에 넣어 95℃에서 2시간 동안 추출후 잔류용매를 제거하여 피버퓨 추출물을 제조하였다. (1) A mixture consisting of leaves, flowers, stems, and roots of Feverfew Herb was extracted in a weight ratio of 1:20 (67 mass% of purified water, 30 mass% of 1,3-butylene glycol, and 1,2-hexane). 3% by weight of diol) was extracted for 2 hours at 95 ℃ to remove the residual solvent to prepare a feverfew extract.
(2) 상기 피버퓨 대신 꿀풀 초본의 어린순, 잎, 꽃, 및 줄기로 구성된 혼합물을 동일한 방법에 의해 추출하여 꿀풀 추출물을 제조하였으며, 오이풀 초본의 뿌리를 동일한 방법에 의해 추출하여 오이풀 추출물을 제조하였다.(2) Instead of the feverfew, a mixture consisting of young shoots, leaves, flowers, and stems of Lamiaceae herb was extracted by the same method, and Lamiaceae extract was prepared by extracting the roots of Cucumber herb by the same method. .
(3) 이렇게 제조된 각 추출물을 정제수를 이용하여 10 부피%로 희석한 후, 하기 표 1의 함량으로 하기 배지로 재차 희석하여 실시예 1 내지 4의 조성물을 제조하였다.(3) Each of the extracts thus prepared was diluted to 10% by volume with purified water, and then diluted again with the following media to the contents of Table 1 to prepare the compositions of Examples 1 to 4.
배지: 소태아 혈청(Fetal Bovine Serum), 100 IU/mL의 페니실린 및 100μg/mL의 스트렙토마이신이 첨가된 RPMI 미디엄(Medium) 1640(시험예 1); Medium: RPMI Medium 1640 (Fetal Bovine Serum), 100 IU / mL penicillin and 100 μg / mL streptomycin added (Test Example 1);
저 세럼 성장 성분(low serum growth supplement)(50X의 저 세럼 성장 성분을 1X가 되도록 배지에 첨가)과 100 units/mL의 스트렙토마이신을 첨가한 섬유아세포주 배지(시험예 2)Fibroblast line medium with low serum growth supplement (add 50X low serum growth component to 1X medium) and 100 units / mL streptomycin (Test Example 2)
(4) 대조예의 경우 아무런 평가 시료(유효 성분)를 첨가하지 않은 것을 의미하며 비교예 1 및 2는 각각 덱사메타손 및 히알루론산을 하기 표 1에 기재된 함량으로 상기 배지로 희석하여 제조하였다.(4) In the case of the control means that no evaluation sample (active ingredient) was added, and Comparative Examples 1 and 2 were prepared by diluting dexamethasone and hyaluronic acid with the above-described media in the amounts shown in Table 1, respectively.
[시험예 1] 식물 추출물의 피부 항염 효과 평가Test Example 1 Evaluation of Skin Anti-inflammatory Effect of Plant Extracts
(1) RAW264.7 세포(한국세포주은행으로부터 입수)를 6-웰 플레이트에 5×105 cell/well의 농도로 각각 분주한 후, 각 웰에 10 부피%의 소태아혈청(GIBCO, Cat.No. 12483-020), 100 IU/mL의 페니실린(SIGMA, Cat.No. P3032) 및 100μg/mL의 스트렙토마이신(SIGMA, Cat.No. S9137)이 첨가된 RPMI 미디엄 1640(GIBCO, 제품번호 61870-036) 배지를 넣고 37℃, 5%의 CO2 하에서(이하 세포 배양시 동일한 조건) 2일간 배양하였다. 배양된 RAW264.7 세포를 PBS로 세척하고 실시예 1 내지 4, 비교예 1 및 대조예를 각 웰에 처리하여 37℃, 5%의 CO2 하에서 3일간 배양하였다.(1) After dispensing RAW264.7 cells (obtained from Korea Cell Line Bank) into 6-well plates at a concentration of 5 × 10 5 cells / well, 10 wells of fetal bovine serum (GIBCO, Cat. No. 12483-020), RPMI Medium 1640 (GIBCO, Catalog No. 61870) with 100 IU / mL penicillin (SIGMA, Cat.No. P3032) and 100 μg / mL streptomycin (SIGMA, Cat.No. S9137). Medium was added and cultured for 2 days at 37 ° C. under 5% CO 2 (the same conditions for cell culture). The cultured RAW264.7 cells were washed with PBS and treated with each well of Examples 1 to 4, Comparative Example 1 and Control Example and incubated for 3 days at 37 ℃, 5% CO 2 .
(2) 배양된 세포에 각각 UVB 또는 과산화수소수를 하기와 같이 처리하여 세포손상을 유도하였다.(2) Each cell was treated with UVB or hydrogen peroxide as follows to induce cell damage.
- UVB 처리에 의한 세포손상-Cell damage by UVB treatment
상기 (1)에서 배양된 세포의 배지를 제거하고 PBS로 세포를 세척하고 UVP 크로스링커스(UVP Crosslinkers)(UVP, United Kingdom)에서 40 mJ/cm2의 UVB를 2시간 동안 조사하여 세포 손상을 유도한 뒤 배지를 교체하여 1일간 배양하였다.Remove the medium of the cells cultured in (1), wash the cells with PBS and induce cell damage by irradiating UVB of 40 mJ / cm 2 for 2 hours in UVP Crosslinkers (UVP, United Kingdom) After replacing the medium and incubated for 1 day.
- 과산화수소수에 의한 세포 손상-Cell damage by hydrogen peroxide
상기 (1)에서 배양된 세포의 배지를 제거하고 PBS로 세포를 세척한 뒤 과산화수소수(DAEJUNG, Korea)를 500μM 의 농도로 세포에 처리하여 1일간 배양하였다.After removing the culture medium of the cells cultured in (1) and washing the cells with PBS, the cells were treated with hydrogen peroxide (DAEJUNG, Korea) at a concentration of 500 μM and cultured for 1 day.
(3) 이렇게 배양된 세포로부터 항염 관련 유전자의 분석을 위하여 하기와 같은 방법으로 RNA를 추출 및 정량한 다음 cDNA를 합성하여 RT-PCR(Reverse transcription-polymerase chain reaction)을 실시하였다.(3) In order to analyze anti-inflammatory genes from the cultured cells, RNA was extracted and quantified in the following manner and cDNA was synthesized to perform RT-PCR (Reverse transcription-polymerase chain reaction).
① 상기 (2)에서 시료와 함께 배양된 세포의 배지를 제거하고 1X PBS로 세포를 세척하였다.① Remove the medium of the cells incubated with the sample in (2) and washed the cells with 1X PBS.
② 1X PBS를 제거하고 플레이트에 배양된 세포의 각 웰에 트리아졸 시약 (Invitrogen, USA)을 세포에 고루 닿도록 넣고 실온에서 3~5분간 방치하였다.② 1X PBS was removed, and the triazole reagent (Invitrogen, USA) was added to each well of the cells incubated in the plate evenly to the cells and allowed to stand at room temperature for 3-5 minutes.
③ 각 웰 안의 세포를 스크래퍼로 조심스럽게 긁어서 마이크로튜브에 모은 뒤 40 μL의 클로로포름을 가하고 섞어주었다.③ Carefully scrape the cells in each well with a scraper, collect in microtubes, add 40 μL of chloroform and mix.
④ 실온에서 2~3분간 방치 후 12,000rpm, 4℃에서 15분간 원심 분리하였다.④ After standing for 2 to 3 minutes at room temperature, centrifuged for 15 minutes at 12,000 rpm, 4 ℃.
⑤ 원심 분리 후 투명한 상등액을 새 튜브에 옮긴 후 100 μL의 이소프로필 알코올을 넣고 조심스럽게 뒤집어(invert) 상온에서 10 분간 방치 후 12,000rpm, 4℃에서 10분간 원심 분리하였다. ⑤ After centrifugation, the transparent supernatant was transferred to a new tube, 100 μL of isopropyl alcohol was added and carefully inverted and left at room temperature for 10 minutes, followed by centrifugation at 12,000 rpm and 4 ° C. for 10 minutes.
⑥ 상등액을 버리고 RNA 펠렛을 DEPC(diethyl pyrocarbonate)가 처리된 정제수로 희석한 75 부피%의 에탄올 200 μL를 넣어 펠렛을 세척해준 뒤 상등액을 버리고 RNA 펠렛을 실온 건조하였다.⑥ After discarding the supernatant and washing the pellet with 200 μL of 75 vol% ethanol diluted with purified water treated with DEPC (diethyl pyrocarbonate), the supernatant was discarded and the RNA pellet was dried at room temperature.
⑦ 건조시킨 RNA 펠렛에 DEPC가 처리된 정제수 50 μL를 넣어 현탁시킨 뒤 55 내지 60℃에서 10분간 가열한다.⑦ Put 50 μL of DEPC treated purified water into the dried RNA pellet and suspend it and heat it for 10 minutes at 55 ~ 60 ℃.
⑧ 그런 뒤, RNA를 260nm에서 흡광도를 통하여 정량하였다.⑧ RNA was then quantified by absorbance at 260 nm.
정량값 구하는 식: 정량값=OD 값 * 희석배수 * 40 μg/mLFormula for quantitative value: quantitative value = OD value * dilution factor * 40 μg / mL
(OD260=1은 40 μg/mL)(OD260 = 1 = 40 μg / mL)
(4) cDNA합성은 PrimeScript 1st strand cDNA Synthesis Kit(TaKaRa, Cat. No 6110A)를 이용하였고 키트의 방법에 의해 실험을 수행하였다. PCR은 Taq polymerase Kit(TaKaRa, Cat. No R001A)를 사용하여 그 키트의 방법에 따라 수행하고 PCR장비(Biofree, Cat. No TC-96/G/H/(b)B)를 이용해 하기 표 2의 프라이머(이하 실험에서 사용된 모든 프라이머는 바이오니아(Daejeon, Korea)에서 주문 제작하였다)로 유전자를 증폭하였다. PCR에 의하여 생성된 산물은 1%의 아가로스 겔에서 전기영동하여 이미지 분석기(KOREALABTECH, Bundang, Korea)로 분석하여 확인하였다.(4) cDNA synthesis was performed using PrimeScript 1st strand cDNA Synthesis Kit (TaKaRa, Cat. No. 6110A) and the experiment was performed by the method of the kit. PCR was performed according to the method of the kit using a Taq polymerase Kit (TaKaRa, Cat.No R001A) and using a PCR equipment (Biofree, Cat.No TC-96 / G / H / (b) B) The gene was amplified with the primer of (all primers used in the following experiment was custom-made in Daejeon, Korea). The product produced by PCR was confirmed by electrophoresis on 1% agarose gel and analyzed by an image analyzer (KOREALABTECH, Bundang, Korea).
Reverse: 5’-CCT TGG TCT GGT AGG AGA CG-3’(서열번호 2)Forward: 5'-CAG AGG GAA GAG TTC CCC AG-3 '(SEQ ID NO: 1)
Reverse: 5'-CCT TGG TCT GGT AGG AGA CG-3 '(SEQ ID NO: 2)
Reverse: 5’- TTT ATG CCT ACA GCC TCC T-3’(서열번호 4)Forward: 5'- TCT CAG CAA TGT CAA CGA C-3 '(SEQ ID NO: 3)
Reverse: 5'- TTT ATG CCT ACA GCC TCC T-3 '(SEQ ID NO: 4)
실시예 1 내지 4, 비교예 1 및 대조예를 처리한 후 TNF-α 및 NF-κB의 발현량 결과를 각각 도 1 내지 4, 및 하기 표 3 내지 6에 나타내었다. 각 유전자의 발현율은 하기 수학식을 이용하여 계산하였다.The results of expression levels of TNF-α and NF-κB after the treatment of Examples 1 to 4, Comparative Example 1 and the control examples are shown in FIGS. 1 to 4 and Tables 3 to 6, respectively. The expression rate of each gene was calculated using the following equation.
[수학식][Equation]
각 유전자의 발현율(%) = (시료 처리시 유전자 발현양/대조군의 유전자 발현 양) X 100% Expression of each gene = (quantity of gene expression / control gene expression in sample treatment)
표 3은 UVB 처리 시 TNF-α의 발현량 결과이고, 표 4는 UVB 처리 시 NF-κB의 발현량 결과이고, 표 5는 과산화수소수 처리 시 TNF-α의 발현량 결과이고 표 6은 과산화수소수 처리 시 NF-κB의 발현량 결과이다. 도 1 내지 도 4는 각각 표 3 내지 표 6의 결과를 그래프로 나타낸 것에 해당한다.Table 3 shows the results of expression of TNF-α in UVB treatment, Table 4 shows the results of expression of NF-κB in UVB treatment, Table 5 shows the results of expression of TNF-α in treatment with hydrogen peroxide and Table 6 shows the number of hydrogen peroxide The result of expression level of NF-κB upon treatment. 1 to 4 correspond to graphs of the results of Tables 3 to 6, respectively.
도 1 내지 4, 및 표 3 내지 6에 따르면 본 발명의 일측면에 따른 실시예 1 내지 4의 조성물로 처리한 경우, UVB 또는 과산화수소수에 의한 손상으로 유도되는 항염 인자들의 발현량이 실시예 1 내지 4에 의해 감소되는 것을 확인할 수 있다.1 to 4, and Tables 3 to 6, when treated with the composition of Examples 1 to 4 according to one aspect of the present invention, the amount of expression of anti-inflammatory factors induced by damage caused by UVB or hydrogen peroxide solution of Examples 1 to 4 It can be seen that the decrease by 4.
구체적으로 표 3 및 도 1에 따르면 피버퓨 추출물(실시예 1), 꿀풀 추출물(실시예 2) 및 오이풀 추출물(실시예 3)은 UVB에 의해 유도된 염증 반응에서 약 25 내지 26% 정도의 TNF-α 발현 저해 효과를 나타내었고, 특히 이들을 모두 조합한 조성물(실시예 4)은 약 40%의 발현 저해 효과를 나타내어 추출물 각각에 비하여 TNF-α의 발현을 현저하게 저해하는 효과를 나타내었다. 이러한 실시예 4의 효과는 비교예 1인 덱사메타손의 발현 억제 효과와 유사한 수준이며, 특히 천연 성분임을 고려하면 실시예 4의 효과는 매우 우수한 것이다.Specifically, according to Table 3 and Figure 1 Feverfew extract (Example 1), Lamiaceae extract (Example 2) and Cucumber extract (Example 3) is about 25 to 26% TNF in the inflammatory response induced by UVB -α expression inhibitory effect, in particular, a combination of all of these compositions (Example 4) showed an expression inhibitory effect of about 40%, significantly inhibiting the expression of TNF-α compared to each of the extracts. The effect of Example 4 is similar to the inhibitory effect of the expression of dexamethasone of Comparative Example 1, especially considering that it is a natural component, the effect of Example 4 is very excellent.
표 4 및 도 2에 따르면 피버퓨 추출물(실시예 1), 꿀풀 추출물(실시예 2) 및 오이풀 추출물(실시예 3)은 UVB에 의해 유도된 염증 반응에서 약 28 내지 30% 정도의 NF-κB 발현 저해 효과를 나타내었고, 특히 이들을 모두 조합한 조성물(실시예 4)은 약 49%의 발현 저해 효과를 나타내어 추출물 각각에 비하여 NF-κB의 발현을 현저하게 저해하는 효과를 나타내었다. 이러한 실시예 4의 효과는 비교예 1인 덱사메타손의 발현 억제 효과보다 우수한 수준이며, 특히 천연 성분임을 고려하면 실시예 4의 효과는 매우 우수한 것이다.According to Table 4 and Figure 2 Feverfew extract (Example 1), Lamiaceae extract (Example 2) and Cucumber extract (Example 3) is about 28 to 30% NF-κB in the inflammatory response induced by UVB In particular, the combination of these compositions (Example 4) exhibited an expression inhibitory effect of about 49%, which significantly inhibited the expression of NF-κB relative to each of the extracts. The effect of Example 4 is higher than the inhibitory effect of the expression of dexamethasone, Comparative Example 1, especially considering that it is a natural component, the effect of Example 4 is very excellent.
표 5 및 도 3에 따르면 피버퓨 추출물(실시예 1), 꿀풀 추출물(실시예 2) 및 오이풀 추출물(실시예 3)은 과산화수소수에 의해 유도된 염증 반응에서 약 28 내지 29% 정도의 TNF-α 발현 저해 효과를 나타내었고, 특히 이들을 모두 조합한 조성물(실시예 4)은 약 53%의 발현 저해 효과를 나타내어 추출물 각각에 비하여 TNF-α의 발현을 현저하게 저해하는 효과를 나타내었다. 이러한 실시예 4의 효과는 비교예 1인 덱사메타손의 발현 억제 효과와 유사한 수준이며, 특히 천연 성분임을 고려하면 실시예 4의 효과는 매우 우수한 것이다.According to Table 5 and Figure 3 Feverfew extract (Example 1), Lamiaceae extract (Example 2) and Cucumber extract (Example 3) is about 28 to 29% TNF- in the inflammatory response induced by hydrogen peroxide α expression inhibitory effect, in particular, a combination of all of these compositions (Example 4) showed an expression inhibitory effect of about 53%, significantly inhibiting the expression of TNF-α compared to each of the extracts. The effect of Example 4 is similar to the inhibitory effect of the expression of dexamethasone of Comparative Example 1, especially considering that it is a natural component, the effect of Example 4 is very excellent.
표 6 및 도 4에 따르면 피버퓨 추출물(실시예 1), 꿀풀 추출물(실시예 2) 및 오이풀 추출물(실시예 3)은 과산화수소수에 의해 유도된 염증 반응에서 약 27 내지 44% 정도의 NF-κB 발현 저해 효과를 나타내었고, 특히 이들을 모두 조합한 조성물(실시예 4)은 약 52%의 발현 저해 효과를 나타내어 추출물 각각에 비하여 NF-κB의 발현을 현저하게 저해하는 효과를 나타내었다. 이러한 실시예 4의 효과는 비교예 1인 덱사메타손의 발현 억제 효과보다 우수한 수준이며, 특히 천연 성분임을 고려하면 실시예 4의 효과는 매우 우수한 것이다.According to Table 6 and Figure 4 Feverfew extract (Example 1), Lamiaceae extract (Example 2) and Cucumber extract (Example 3) is about NF- of about 27 to 44% in the inflammatory response induced by hydrogen peroxide κB expression inhibitory effect was shown, and in particular, the composition combining all of them (Example 4) showed an expression inhibitory effect of about 52%, significantly inhibiting the expression of NF-κB relative to each of the extracts. The effect of Example 4 is higher than the inhibitory effect of the expression of dexamethasone, Comparative Example 1, especially considering that it is a natural component, the effect of Example 4 is very excellent.
상기 결과를 통하여 본 발명의 일측면에 따른 조성물이 현저한 피부 항염 효과를 나타낸다는 점을 확인할 수 있다.Through the above results it can be confirmed that the composition according to one aspect of the present invention shows a significant skin anti-inflammatory effect.
[시험예 2] 식물 추출물의 피부 보습 효과 평가Test Example 2 Evaluation of Skin Moisturizing Effect of Plant Extract
(1) 사람 섬유아 세포주(human dermal fibroblast)인 HDFa세포(ThermoFisher SCIENTIFIC)를 6-웰 플레이트에 5×105 cells/well의 농도로 각 웰에 분주한 후, 저 세럼 성장 성분(LSGS, Gibco BRL, Grand Island, NY, USA)(50X의 저 세럼 성장 성분을 1X가 되도록 배지에 첨가)과 100 units/mL의 스트렙토마이신(Sigma-Aldrich Co., St. Louis, MO, USA)을 첨가한 섬유아세포주 기본 배지(Medium 106, Gibco, 제품번호: M-106-500)를 각 웰에 넣고 37℃, 5%의 CO2 하에서 2일간 배양하였다. (1) After dispensing HDFa cells (ThermoFisher SCIENTIFIC), which is a human dermal fibroblast, into each well at a concentration of 5 × 10 5 cells / well in a 6-well plate, low serum growth components (LSGS, Gibco) BRL, Grand Island, NY, USA) (adding 50X of low serum growth to the medium to 1X) and 100 units / mL of streptomycin (Sigma-Aldrich Co., St. Louis, MO, USA) Fibroblast line basal medium (Medium 106, Gibco, product number: M-106-500) was added to each well and incubated at 37 ° C., 5% CO 2 for 2 days.
(2) 배양된 HDFa를 PBS로 세척하고 배지 교체와 함께 실시예 1 내지 4, 비교예 2 및 대조예로 처리하여 37℃, 5%의 CO2 하에서 3일간 배양하였다.(2) The cultured HDFa was washed with PBS and treated with Examples 1 to 4, Comparative Example 2 and Control with medium replacement and incubated under 37 ° C., 5% CO 2 for 3 days.
(3) 이렇게 배양된 세포에서 상기 시험예 1의 (3) 및 (4)의 방법에 따르되, 하기 표 7의 프라미어를 사용하여 HAS-3(Hyalruronan synthase 3)와 아쿠아포린의 발현량을 측정하였다.(3) According to the method of Test Example 1 (3) and (4) in the cultured cells as described above, using the primers of Table 7 below to measure the expression level of HAS-3 (Hyalruronan synthase 3) and aquaporin It was.
Reverse: 5’- AGA GGA GGG AGT AGA GGG AC-3’(서열번호 6)Forward: 5'- GGA AAG CTT GGC ATG TAC CGC AAC AG-3 '(SEQ ID NO: 5)
Reverse: 5'- AGA GGA GGG AGT AGA GGG AC-3 '(SEQ ID NO: 6)
Reverse: 5’- TCT GCT CCT TGT GCT TCA CAT-3’(서열번호 8)Forward: 5'- ACC CTC ATC CTG GTG ATG TTT G-3 '(SEQ ID NO: 7)
Reverse: 5'- TCT GCT CCT TGT GCT TCA CAT-3 '(SEQ ID NO: 8)
그리고 상기 수학식을 이용하여 계산된 각 유전자의 발현율을 각각 도 5, 도 6, 및 표 8, 표 9에 나타내었다. 표 8은 HAS-3의 유전자 발현량 결과이고, 표 9는 아쿠아포린의 유전자 발현량 결과이다. 도 5 및 7은 각각 표 8 및 표 9의 결과를 그래프로 나타낸 것이다.And the expression rate of each gene calculated using the above equation is shown in Figure 5, Figure 6, Table 8, Table 9, respectively. Table 8 shows the results of gene expression of HAS-3, and Table 9 shows the results of gene expression of aquaporin. 5 and 7 graphically show the results of Tables 8 and 9, respectively.
표 8, 표 9, 도 5 및 6의 결과에 따르면 본 발명의 일측면에 따른 실시예 1 내지 4의 조성물로 처리한 경우 보습과 관련된 인자들의 발현을 촉진하는 것을 확인할 수 있다.According to the results of Table 8, Table 9, 5 and 6 it can be seen that when treated with the composition of Examples 1 to 4 according to one aspect of the present invention promotes the expression of factors related to moisturizing.
구체적으로 표 8 및 도 5에 따르면 피버퓨 추출물(실시예 1), 꿀풀 추출물(실시예 2) 및 오이풀 추출물(실시예 3)은 HAS-3 유전자의 발현을 약 12 내지 28% 정도 촉진시키는 효과를 나타내었고, 특히 이들을 모두 조합한 조성물(실시예 4)은 약 34%의 유전자 발현 촉진 효과를 나타내어 추출물 각각에 비해 HAS-3 유전자의 발현을 현저하게 촉진하는 효과를 나타내었다.Specifically, according to Table 8 and Figure 5 Feverfew extract (Example 1), Lamiaceae extract (Example 2) and Cucumber extract (Example 3) the effect of promoting the expression of HAS-3 gene about 12 to 28% In particular, a combination of all of these compositions (Example 4) showed a gene expression promoting effect of about 34%, showing an effect of significantly promoting the expression of the HAS-3 gene compared to each of the extracts.
또한 표 9 및 도 6에 따르면 피버퓨 추출물(실시예 1), 꿀풀 추출물(실시예 2) 및 오이풀 추출물(실시예 3)은 아쿠아포린 유전자의 발현을 약 12 내지 28% 정도 촉진시키는 효과를 나타내었고, 특히 이들을 모두 조합한 조성물(실시예 4)은 약 51%의 유전자 발현 촉진 효과를 나타내어 추출물 각각에 비해 아쿠아포린 유전자의 발현을 현저하게 촉진하는 효과를 나타내었다. 이러한 실시예 4의 결과는 비교예 2인 히알루론산의 결과보다 우수한 수준이며, 특히 천연 성분임을 고려하면 실시예 4의 효과는 매우 우수한 것이다.In addition, according to Table 9 and Figure 6 Feverfew extract (Example 1), Lamiaceae extract (Example 2) and Cucumber extract (Example 3) has an effect of promoting the expression of aquaporin gene about 12 to 28% In particular, the combination of all of these compositions (Example 4) exhibited a gene expression promoting effect of about 51%, showing an effect of significantly promoting the expression of the aquaporin gene compared to each of the extracts. The result of Example 4 is higher than that of the hyaluronic acid of Comparative Example 2, especially considering that it is a natural component, the effect of Example 4 is very excellent.
이러한 결과를 통하여 본 발명의 일측면에 따른 조성물이 현저하게 우수한 보습 효과를 나타낸다는 점을 확인할 수 있다.Through these results it can be confirmed that the composition according to one aspect of the present invention shows a remarkably excellent moisturizing effect.
그러므로, 상기 시험예 1 및 2의 결과에 따르면 본 발명의 일측면에 따른 조성물은 현저하게 우수한 피부 항염 및 피부 보습 효과를 가지며, 그로 인해 피부를 보호하고 건강하게 유지시킨다는 점을 확인할 수 있다.Therefore, according to the results of Test Examples 1 and 2 it can be seen that the composition according to one aspect of the present invention has a remarkably excellent skin anti-inflammatory and skin moisturizing effect, thereby protecting and maintaining the skin healthy.
본 발명의 일 측면에 따른 조성물의 제형예를 아래에서 설명하나, 이외의 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 명세서를 제한하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Examples of the formulation of the composition according to an aspect of the present invention will be described below, but can be applied to various other formulations, which are intended to explain in detail only, not intended to limit the present specification.
[제형예 1] 유연화장수(스킨로션)Formulation Example 1 Flexible Cosmetic (Skin Lotion)
하기 표 10에 기재된 조성에 따라 통상적인 방법으로 유연화장수를 제조하였다.According to the composition described in Table 10 below to prepare a flexible longevity in a conventional manner.
[제형예 2] 영양화장수(밀크로션)Formulation Example 2 Nutrients (Milk Lotion)
하기 표 11에 기재된 조성에 따라 통상적인 방법으로 영양화장수를 제조하였다.Nutrients were prepared in a conventional manner according to the composition shown in Table 11.
[제형예 3] 영양크림Formulation Example 3 Nutrition Cream
하기 표 12에 기재된 조성에 따라 통상적인 방법으로 영양크림을 제조하였다.Nutritional cream was prepared in a conventional manner according to the composition shown in Table 12.
[제형예 4] 마사지 크림Formulation Example 4 Massage Cream
하기 표 13에 기재된 조성에 따라 통상적인 방법으로 마사지 크림을 제조하였다.To prepare a massage cream in a conventional manner according to the composition described in Table 13.
[제형예 5] 팩[Formulation Example 5] Pack
하기 표 14에 기재된 조성에 따라 통상적인 방법으로 팩을 제조하였다.To prepare a pack in a conventional manner according to the composition described in Table 14.
이상으로 본 명세서의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 명세서의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 명세서의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As described above in detail a specific part of the present specification, it is apparent to those skilled in the art that the specific description is merely a preferred embodiment, and the scope of the present specification is not limited thereto. Therefore, the substantial scope of the present specification will be defined by the appended claims and equivalents thereof.
<110> Yuhan-Kimberly, Limited <120> COMPOSITION FOR ANTI-INFLAMMATORY OR MOISTURIZING ON SKIN COMPRISING PLANT EXTARCT <130> KC161016 <160> 8 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer of TNF-alpha <400> 1 cagagggaag agttccccag 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer of TNF-alpha <400> 2 ccttggtctg gtaggagacg 20 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Forward primer of NF-kappa B <400> 3 tctcagcaat gtcaacgac 19 <210> 4 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer of NF-kappa B <400> 4 tttatgccta cagcctcct 19 <210> 5 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Forward primer of HAS-3 <400> 5 ggaaagcttg gcatgtaccg caacag 26 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer of HAS-3 <400> 6 agaggaggga gtagagggac 20 <210> 7 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Forward primer of Aquaporin <400> 7 accctcatcc tggtgatgtt tg 22 <210> 8 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer of Aquaporin <400> 8 tctgctcctt gtgcttcaca t 21 <110> Yuhan-Kimberly, Limited <120> COMPOSITION FOR ANTI-INFLAMMATORY OR MOISTURIZING ON SKIN COMPRISING PLANT EXTARCT <130> KC161016 <160> 8 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer of TNF-alpha <400> 1 cagagggaag agttccccag 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer of TNF-alpha <400> 2 ccttggtctg gtaggagacg 20 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Forward primer of NF-kappa B <400> 3 tctcagcaat gtcaacgac 19 <210> 4 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer of NF-kappa B <400> 4 tttatgccta cagcctcct 19 <210> 5 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Forward primer of HAS-3 <400> 5 ggaaagcttg gcatgtaccg caacag 26 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer of HAS-3 <400> 6 agaggaggga gtagagggac 20 <210> 7 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Forward primer of Aquaporin <400> 7 accctcatcc tggtgatgtt tg 22 <210> 8 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer of Aquaporin <400> 8 tctgctcctt gtgcttcaca t 21
Claims (11)
조성물의 총 부피에 대하여 추출물의 총 함량은 0.0001 내지 20 부피%인 피부 항염 또는 피부 보습용 조성물.The method of claim 1,
The total content of the extract is 0.0001 to 20% by volume relative to the total volume of the composition for skin anti-inflammatory or skin moisturizing composition.
상기 피버퓨 추출물은 피버퓨 초본의 잎, 꽃, 줄기, 뿌리 및 이들의 조합으로 구성된 군으로부터 선택된 하나 이상의 추출물인 피부 항염 또는 피부 보습용 조성물.The method of claim 1,
The feverfew extract is one or more extracts selected from the group consisting of feverfew herbal leaves, flowers, stems, roots, and combinations thereof.
상기 꿀풀 추출물은 꿀풀 초본의 어린순, 잎, 꽃, 줄기 및 이들의 조합으로 구성된 군으로부터 선택된 하나 이상의 추출물인 피부 항염 또는 피부 보습용 조성물.The method of claim 1,
The nectar extract is a skin anti-inflammatory or skin moisturizing composition is one or more extracts selected from the group consisting of young shoots, leaves, flowers, stems and combinations of nectar herb.
상기 오이풀 추출물은 오이풀 초본의 뿌리 추출물인 피부 항염 또는 피부 보습용 조성물.The method of claim 1,
The cucumber extract is a skin anti-inflammatory or skin moisturizing composition which is a root extract of cucumber herb.
상기 조성물은 항산화제, 보존제, 흡수제, 각질제거제, 증점제, 선크림제제, 유화제, 계면활성제, 향료, 소취제, 안정화제, 피부 보호제, 및 pH 조절제 중 하나 이상을 더 포함하는 피부 항염 또는 피부 보습용 조성물.The method of claim 1,
The composition may further comprise at least one of an antioxidant, a preservative, an absorbent, an exfoliant, a thickener, a sunscreen, an emulsifier, a surfactant, a perfume, a deodorant, a stabilizer, a skin protectant, and a pH adjusting agent. .
상기 화장품은 기초 화장품, 메이크업 화장품, 헤어케어 화장품, 얼굴 케어 화장품, 및 바디케어 화장품으로 구성된 군으로부터 선택된 어느 하나인 피부 항염 또는 피부 보습용 조성물.The method of claim 1,
The cosmetic is a composition for anti-inflammatory or skin moisturizing any one selected from the group consisting of basic cosmetics, makeup cosmetics, hair care cosmetics, facial care cosmetics, and body care cosmetics.
상기 위생용품은 물티슈, 티슈, 기저귀, 생리대, 위생 와이프, 습윤 와이프, 클리닝 와이프, 훼이셜 와이프, 스킨케어 와이프, 및 지한제 와이프로 구성된 군으로부터 선택된 어느 하나인 피부 항염 또는 피부 보습용 조성물.The method of claim 1,
The hygiene article is any one selected from the group consisting of wet wipes, tissues, diapers, sanitary napkins, sanitary wipes, wet wipes, cleaning wipes, facial wipes, skin care wipes, and antiperspirant wipes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160061627A KR102085052B1 (en) | 2016-05-19 | 2016-05-19 | Composition for anti-inflammatory or moisturizing on skin comprising plant extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160061627A KR102085052B1 (en) | 2016-05-19 | 2016-05-19 | Composition for anti-inflammatory or moisturizing on skin comprising plant extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170130865A KR20170130865A (en) | 2017-11-29 |
| KR102085052B1 true KR102085052B1 (en) | 2020-03-05 |
Family
ID=60812181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160061627A Active KR102085052B1 (en) | 2016-05-19 | 2016-05-19 | Composition for anti-inflammatory or moisturizing on skin comprising plant extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102085052B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102028745B1 (en) * | 2018-05-09 | 2019-10-04 | 주식회사 스킨리더 | Composition for peel-off pack |
| KR102293978B1 (en) * | 2020-04-24 | 2021-08-27 | 주식회사 지크린 | Water tissue containing disinfectant composition comprising hydrogen peroxide |
| KR20240088083A (en) | 2022-12-13 | 2024-06-20 | 한국콜마주식회사 | Cosmetic Composition Comprising Bacopa Monnieri |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101582974B1 (en) * | 2015-08-07 | 2016-01-06 | (주)더마랩 | Composition for improving skin condition containing the complex extracts of Hydrolyzed Manihot Esculenta Tuber and Chrysanthemum Parthenium |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100656287B1 (en) | 2004-12-09 | 2006-12-11 | 학교법인 한림대학교 | Anti-Inflammatory Agents Including Bellflower Extract |
| KR101020536B1 (en) * | 2008-05-09 | 2011-03-09 | (주)더페이스샵 | Cosmetic composition for moisturizing skin containing cucumber extract and method for producing same |
| KR101615417B1 (en) * | 2013-07-23 | 2016-04-25 | 남부대학교산학협력단 | Korean herb cosmetic composition with the anti-oxidant, whitening and ant-inflammatory effect |
| KR101575722B1 (en) | 2013-10-28 | 2015-12-09 | 명지대학교 산학협력단 | Composition comprising the cornus officinalis extract for anti-oxidant, anti-bacterial, anti-inflammatory effect |
| KR20160054678A (en) * | 2014-11-06 | 2016-05-17 | 주식회사 엘지생활건강 | Composition for promoting synthesis of hyaluronic acid comprising Prunellae spica extracts and the use thereof |
-
2016
- 2016-05-19 KR KR1020160061627A patent/KR102085052B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101582974B1 (en) * | 2015-08-07 | 2016-01-06 | (주)더마랩 | Composition for improving skin condition containing the complex extracts of Hydrolyzed Manihot Esculenta Tuber and Chrysanthemum Parthenium |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170130865A (en) | 2017-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102171133B1 (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
| JP5683134B2 (en) | Topical skin preparation | |
| KR20110057895A (en) | Skin external preparation composition for promoting hyaluronic acid production containing ginsenoside R and ginsenoside compound VII | |
| EP2735304A2 (en) | Composition for preventing or alleviating skin wrinkles containing honeybush extract or a fermented liquor thereof as an active ingredient | |
| KR102085052B1 (en) | Composition for anti-inflammatory or moisturizing on skin comprising plant extract | |
| KR102068194B1 (en) | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract | |
| JP2020502172A (en) | Cosmetic composition containing Chinese herbal extract as active ingredient | |
| KR100513659B1 (en) | Cosmetic Composition for Improving Atopic Dermatitis Containing Extracts from Plants as Active Ingredient | |
| KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| US20180353413A9 (en) | Skin compositions containing hydrocortisone | |
| CN119818548A (en) | Skin improving composition comprising culture of Parsley | |
| JP2003171225A (en) | Composition for promoting integrin α6β4 production | |
| JP6175216B2 (en) | Preventive and therapeutic agents for arthritis | |
| KR20210018388A (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| JP2005008548A (en) | Skin preparation | |
| JP2008184441A (en) | Skin preparation for cell growth promotion | |
| JP6723979B2 (en) | Wrinkle improver | |
| CN100413489C (en) | Mingyi balance conditioning repair cream | |
| KR20100067700A (en) | Cosmetic compositions for skin care containing extract of tussilago farfara linne flower | |
| KR101469810B1 (en) | Cosmetic composition containing Ginsenoside Rd and Ginsenoside F2 for improving skin wrinkle | |
| JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
| JP6843537B2 (en) | Anti-skin aging agent and topical cosmetics containing it | |
| KR102561148B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR100507292B1 (en) | A compositions containing Anthriscus sylvestris Hoffmann extract or Petroselinum sativum Miller extract for external application having effects of improving skin wrinkle | |
| JP7680990B2 (en) | Skin dullness improver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160519 |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180706 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20160519 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190730 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200220 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200228 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200302 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20230220 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240228 Start annual number: 5 End annual number: 5 |